COMP <GO>
OVID vs MRK // GROSS PROFIT MARGIN
Ovid Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: OVID 3
— MRK 7
■ METRIC PARITY
LAST: $2.54 (-0.78%) • MKT CAP: $500.0M
gross-margins
—
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OVID VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OVID | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.50% | 20.70% | -49.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.67% | 3.42% | -11.09 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 1.30% | +178.70 | OVID | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.46 | 5.19 | +6.27 | OVID | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 51.7 | +5.20 | OVID | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $500.0M | $361.02B | -$360.52B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OVID REV | MRK REV | OVID GROSS % | MRK GROSS % | OVID FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.3M | $65.01B | — | 74.8% | -$38.3M | $12.36B |
| FY 2024 | $566.0K | $64.17B | — | 76.3% | -$56.0M | $18.10B |
| FY 2023 | $392.0K | $60.12B | — | — | -$45.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OVID // BETA —
MRK // BETA 0.92